Immune-Metabolic Regulation of Biliary Atresia
Immune-Metabolic Regulation of Biliary Atresia
批准号:
10645435
负责人:
Sarah Ann Taylor
金额:
$11.66万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-04-15 至 2025-03-31
关键词:
2 year oldATAC-seqAnti-Inflammatory AgentsApoptoticAreaArginineBile fluidBiliaryBiliary AtresiaBiochemical PathwayBiological AssayBiologyCellsCharacteristicsChildhoodCholestasisChromatinClinicalCollaborationsCritical PathwaysDataDiagnosisDiseaseDrainage procedureEarly identificationEpigenetic ProcessFoundationsFreezingFutureGene ExpressionGene Expression ProfileGene Expression RegulationGenesGenetic TranscriptionGranulocyte-Macrophage Colony-Stimulating FactorHepaticHepatocyteHumanImmuneImmune responseInfantInflammatoryLiverMacrophageMeasuresMedicalMentorsMetabolicMetabolismModificationMusNatureNitric Oxide SynthaseObstructionOperative Surgical ProceduresOutcomePathogenesisPathway interactionsPatient-Focused OutcomesPatientsPhenotypePolyaminesPredictive ValuePrognostic MarkerPutrescineROC CurveRegulationResearchResearch PersonnelRheumatologyRoleRunningSamplingSerumSpermidineSpermineSurvival RateTimeTransplantationTransposaseUp-RegulationValidationcell dedifferentiationcohortdifferential expressionepigenetic regulationhydrophilicityimmunoregulationinfancyinnovationliver transplantationmetabolomicsmonocytenew therapeutic targetnovelprognosticprogramsrecruitsingle nucleus RNA-sequencingsurvival predictiontotal measurement Bilirubintranscriptional reprogrammingtreatment strategyuptake
中文摘要
胆道闭锁(BA)是一种婴幼儿胆汁淤积性肝病,是儿童胆汁淤积性肝病的主要病因。
肝脏移植。目前的证据支持BA起源于一种异常的原理
对环境触发的免疫反应。然而,疾病的确切机制仍然存在。
未知。巨噬细胞(M)在人类和小鼠的BA中都有牵连,而M则是
本质上是异质性的,代谢网络负责促进恢复与促进
炎症性M-极化尚未定义。我们的中心前提是识别
与患者预后相关的巨噬细胞特异性免疫代谢特征将导致
新的预后生物标记物和细胞亚群特异性治疗延长无移植生存期。
我们首次在BA婴儿中发现了一个预后代谢物信号
诊断。我们已经证明,血清精氨酸代谢产物的明显变化,尤其是
诊断时BA婴儿的多胺增加与增加有关
尽管临床上没有基线差异,但2岁时有天然肝脏(SNL)的存活率
特点。已知多胺可将M重新编程为抗炎表型,在
部分通过胞吐作用(即细胞凋亡摄取)。我们的初步数据发现,BA患者
具有多胺高代谢特征的患者以前的肝脏数量增加
特征为单核细胞样M(MLM),与以下相关基因表达增加
单核细胞)和血清GM-CSF。因此,我们假设招募的传销促进肝脏
对胆道梗阻的适应;因此,MLM的代谢和表观遗传重新编程
抗炎表型在2岁时与SNL相关。去调查
这一假设,我们将:1)定义血清精氨酸代谢产物的预后作用,以及2)
鉴定与SNL相关的细胞亚群特异性转录表型。
英文摘要
Biliary atresia (BA) is a cholestatic liver disease of infancy and is the leading cause of pediatric
liver transplantation. Current evidence supports the principle that BA arises from an aberrant
immune response to an environmental trigger. However, the exact mechanism of disease remains
unknown. While macrophages (M) have been implicated in both human and murine BA, M are
heterogeneous by nature and the metabolic networks responsible for pro-restorative vs pro-
inflammatory M polarization have not been defined. Our central premise is that identifying
macrophage-specific immune-metabolic signatures associated with patient outcome will lead to
novel prognostic biomarkers and cell-subset specific therapies to prolong transplant-free survival.
We have been the first to identify a prognostic metabolite signature in BA infants at the time of
diagnosis. We have shown that distinct changes in serum arginine metabolites, particularly
increased polyamines, in BA infants at the time of diagnosis was associated with increased
survival with native liver (SNL) at the age of 2 years despite no baseline differences in clinical
characteristics. Polyamines are known to reprogram M to an anti-inflammatory phenotype, in
part through efferocytosis (i.e. apoptotic cell uptake). Our preliminary data found that BA patients
with a polyamine-high metabolic signature had increased hepatic numbers of previously
characterized monocyte-like M (MLM, increased expression for genes associated with
monocytes) and serum GM-CSF. We thereby hypothesize that recruited MLM promote hepatic
adaptation to biliary obstruction; thus, metabolic and epigenetic reprogramming of MLM towards
and anti-inflammatory phenotype will be associated with SNL at 2 years of age. To investigate
this hypothesis, we will: 1) define the prognostic role for serum arginine metabolites, and 2)
identify cell subset specific transcriptional phenotypes associated with SNL.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Macrophage Regulation of Immune Pathogenesis of Biliary Atresia
-
批准号:10543779
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Sarah Ann Taylor
-
依托单位:
Macrophage Regulation of Immune Pathogenesis of Biliary Atresia
-
批准号:10761123
-
项目类别:
-
资助金额:$16.29万
-
财政年份:2021
-
负责人:Sarah Ann Taylor
-
依托单位:
Macrophage Regulation of Immune Pathogenesis of Biliary Atresia
-
批准号:10320943
-
项目类别:
-
资助金额:$16.3万
-
财政年份:2021
-
负责人:Sarah Ann Taylor
-
依托单位:
Immune Modulation of Macrophages in Obstructive Cholestasis
-
批准号:10040905
-
项目类别:
-
资助金额:$24.42万
-
财政年份:2020
-
负责人:Sarah Ann Taylor
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于ATAC-seq与DNA甲基化测序探究染色质可及性对莲两生态型地下茎适应性分化的作用机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
利用ATAC-seq联合RNA-seq分析TOP2A介导的HCC肿瘤细胞迁移侵
袭的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:柳静
-
依托单位:
面向图神经网络ATAC-seq模体识别的最小间隔单细胞聚类研究
-
批准号:62302218
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:张双全
-
依托单位:
基于ATAC-seq策略挖掘穿心莲基因组中调控穿心莲内酯合成的增强子
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:黄铭坤
-
依托单位:
基于单细胞ATAC-seq技术的C4光合调控分子机制研究
-
批准号:32100438
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:涂晓雨
-
依托单位:
基于ATAC-seq技术研究交叉反应物质197调控TFEB介导的自噬抑制子宫内膜异位症侵袭的分子机制
-
批准号:82001520
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:汤小晗
-
依托单位:
靶向治疗动态调控肺癌细胞DNA可接近性的ATAC-seq分析
-
批准号:81802809
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:蔡梅春
-
依托单位:
运用ATAC-seq技术分析染色质可接近性对犏牛初级精母细胞基因表达的调控作用
-
批准号:31802046
-
项目类别:青年科学基金项目
-
资助金额:27.0万元
-
批准年份:2018
-
负责人:张龚炜
-
依托单位:
基于ATAC-seq和RNA-seq研究CWIN调控采后番茄果实耐冷性作用机制
-
批准号:31801915
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2018
-
负责人:茹磊
-
依托单位:
基于ATAC-seq高精度预测染色质相互作用的新方法和基于增强现实的3D基因组数据可视化
-
批准号:31871331
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2018
-
负责人:张治华
-
依托单位: